Log in

NASDAQ:SPNESeaSpine Stock Price, Forecast & News

$9.59
+0.52 (+5.73 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.07
Now: $9.59
$9.65
50-Day Range
$9.07
MA: $10.95
$12.33
52-Week Range
$4.02
Now: $9.59
$16.78
Volume96,100 shs
Average Volume146,058 shs
Market Capitalization$261.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Read More
SeaSpine logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPNE
CUSIPN/A
Phone760-727-8399

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$159.08 million
Book Value$5.74 per share

Profitability

Net Income$-39,280,000.00

Miscellaneous

Employees361
Market Cap$261.23 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SPNE and its competitors with MarketBeat's FREE daily newsletter.

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

How has SeaSpine's stock been impacted by COVID-19 (Coronavirus)?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SPNE shares have decreased by 10.6% and is now trading at $9.59. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SeaSpine?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SeaSpine.

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for SeaSpine.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Corp (NASDAQ:SPNE) posted its quarterly earnings data on Wednesday, May, 6th. The medical equipment provider reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.06. The medical equipment provider had revenue of $36.11 million for the quarter, compared to the consensus estimate of $35.89 million. SeaSpine had a negative net margin of 26.93% and a negative return on equity of 27.09%. View SeaSpine's earnings history.

What price target have analysts set for SPNE?

5 analysts have issued 12 month target prices for SeaSpine's stock. Their forecasts range from $10.00 to $21.00. On average, they anticipate SeaSpine's share price to reach $16.80 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price. View analysts' price targets for SeaSpine.

Has SeaSpine been receiving favorable news coverage?

News coverage about SPNE stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SeaSpine earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about SeaSpine.

Who are some of SeaSpine's key competitors?

What other stocks do shareholders of SeaSpine own?

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
  • Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Carrie Mendivil, Head of Investor Relations
  • Mr. John J. Winge, VP of Sales (Age 52)

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a number of retail and institutional investors. Top institutional investors include Wedge Capital Management L L P NC (0.54%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Valentine, Richard E Caruso and Stuart Essig. View institutional ownership trends for SeaSpine.

Which institutional investors are selling SeaSpine stock?

SPNE stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View insider buying and selling activity for SeaSpine.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $9.59.

How big of a company is SeaSpine?

SeaSpine has a market capitalization of $261.23 million and generates $159.08 million in revenue each year. The medical equipment provider earns $-39,280,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. SeaSpine employs 361 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.